Cytomed Therapeutics Limited Stock Current Asset
| GDTC Stock | 2.55 0.08 3.24% |
CytoMed Therapeutics Limited fundamentals help investors to digest information that contributes to CytoMed Therapeutics' financial success or failures. It also enables traders to predict the movement of CytoMed Stock. The fundamental analysis module provides a way to measure CytoMed Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to CytoMed Therapeutics stock.
The current year's Total Current Assets is expected to grow to about 12.2 M, whereas Non Current Assets Total are forecasted to decline to about 2.3 M. CytoMed | Current Asset |
CytoMed Therapeutics Limited Company Current Asset Analysis
CytoMed Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
CytoMed Current Asset Historical Pattern
Today, most investors in CytoMed Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various CytoMed Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of CytoMed Therapeutics current asset as a starting point in their analysis.
CytoMed Therapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
CytoMed Total Assets
Total Assets |
|
In accordance with the recently published financial statements, CytoMed Therapeutics Limited has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all United States stocks is 100.0% higher than that of the company.
CytoMed Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CytoMed Therapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CytoMed Therapeutics could also be used in its relative valuation, which is a method of valuing CytoMed Therapeutics by comparing valuation metrics of similar companies.CytoMed Therapeutics is currently under evaluation in current asset category among its peers.
CytoMed Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of CytoMed Therapeutics from analyzing CytoMed Therapeutics' financial statements. These drivers represent accounts that assess CytoMed Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CytoMed Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 25.2M | 28.3M | 33.6M | 43.5M | 39.2M | 24.5M |
CytoMed Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, CytoMed Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to CytoMed Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
CytoMed Fundamentals
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (7.36) % | ||||
| Current Valuation | 24.04 M | ||||
| Shares Outstanding | 11.54 M | ||||
| Shares Owned By Insiders | 69.27 % | ||||
| Shares Owned By Institutions | 0.04 % | ||||
| Number Of Shares Shorted | 82.17 K | ||||
| Price To Book | 3.80 X | ||||
| Price To Sales | 63.67 X | ||||
| Revenue | 290.56 K | ||||
| Gross Profit | 355.19 K | ||||
| EBITDA | (2.94 M) | ||||
| Net Income | (3.13 M) | ||||
| Total Debt | 448.02 K | ||||
| Book Value Per Share | 0.88 X | ||||
| Cash Flow From Operations | (2.59 M) | ||||
| Short Ratio | 4.21 X | ||||
| Earnings Per Share | (0.22) X | ||||
| Target Price | 5.0 | ||||
| Market Capitalization | 26.17 M | ||||
| Total Asset | 12.37 M | ||||
| Retained Earnings | (9.35 M) | ||||
| Working Capital | 9.38 M | ||||
| Net Asset | 12.37 M |
About CytoMed Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CytoMed Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CytoMed Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CytoMed Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CytoMed Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytoMed Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomed Therapeutics Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomed Therapeutics Limited Stock:Check out CytoMed Therapeutics Piotroski F Score and CytoMed Therapeutics Altman Z Score analysis. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CytoMed Therapeutics. If investors know CytoMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CytoMed Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.22) | Revenue Per Share | Quarterly Revenue Growth (0.21) | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CytoMed Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.